Search
Design Therapeutics Inc
DSGNAdd to Watchlist
12.240USD
-0.120-0.97%
Close 09-23 16:00（ET）
764.51MMarket Cap
LossP/E TTM
Design Therapeutics Inc (DSGN) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Design Therapeutics Inc in the past month.
Buy
3 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
21.000USD+69.90%
DSGN Analyst Recommendation Trends
In the current month, DSGN has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DSGN average Analyst price target in the last month is 21.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
1
1
0
0
4
4
3
3
3
3
3
2
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
6
6
5
5
4
3
DSGN Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, DSGN EPS is projected to reach -0.353 in FY2026Q3, following reported EPS of -0.323 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.35
-0.33
-0.34
-0.35
-0.40
Actual
-0.27
-0.29
-0.32
--
--
Surprise
+23.08%
+12.57%
+6.30%
--
--
FAQs
What is Design Therapeutics Inc's price target?
Analysts forecast that Design Therapeutics Inc's price target is USD 21.00, with the highest forecast at USD 22.00 and the lowest forecast at USD 20.00.
How have Design Therapeutics IncDSGN's recent earnings per share performed?
The market expectation was USD -0.32, while Design Therapeutics IncDSGN's earnings per share (EPS) for the previous quarter was USD -0.29. EPS for the next quarter is expected at USD -0.35.
What is the analyst rating for Design Therapeutics Inc?
Based on the ratings of Design Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.